



**Australian Government**  
**Department of Health**

# COMMUNICABLE DISEASES INTELLIGENCE

2019 Volume 43

<https://doi.org/10.33321/cdi.2019.43.27>

## **Australian Gonococcal Surveillance Programme, 1 January to 31 March 2018**

Monica M Lahra and Rodney P Enriquez

The World Health Organisation Collaborating Centre for STI and AMR  
and Neisseria Reference Laboratory, New South Wales Health Pathology,  
Prince of Wales Hospital, Randwick, NSW, 2031 for The National Neisseria  
Network, Australia

# Communicable Diseases Intelligence

ISSN: 2209-6051 Online

This journal is indexed by Index Medicus and Medline.

Creative Commons Licence - Attribution-NonCommercial-NoDerivatives CC BY-NC-ND

© 2019 Commonwealth of Australia as represented by the Department of Health

This publication is licensed under a Creative Commons Attribution-Non-Commercial NoDerivatives 4.0 International Licence from <https://creativecommons.org/licenses/by-nc-nd/4.0/legalcode> (Licence). You must read and understand the Licence before using any material from this publication.

## Restrictions

The Licence does not cover, and there is no permission given for, use of any of the following material found in this publication (if any):

- the Commonwealth Coat of Arms (by way of information, the terms under which the Coat of Arms may be used can be found at [www.itsanhonour.gov.au](http://www.itsanhonour.gov.au));
- any logos (including the Department of Health's logo) and trademarks;
- any photographs and images;
- any signatures; and
- any material belonging to third parties.

## Disclaimer

Opinions expressed in Communicable Diseases Intelligence are those of the authors and not necessarily those of the Australian Government Department of Health or the Communicable Diseases Network Australia. Data may be subject to revision.

## Enquiries

Enquiries regarding any other use of this publication should be addressed to the Communication Branch, Department of Health, GPO Box 9848, Canberra ACT 2601, or via e-mail to: [copyright@health.gov.au](mailto:copyright@health.gov.au)

## Communicable Diseases Network Australia

Communicable Diseases Intelligence contributes to the work of the Communicable Diseases Network Australia.  
<http://www.health.gov.au/cdna>



Communicable Diseases Intelligence (CDI) is a peer-reviewed scientific journal published by the Office of Health Protection, Department of Health. The journal aims to disseminate information on the epidemiology, surveillance, prevention and control of communicable diseases of relevance to Australia.

## Editor

Cindy Toms

## Deputy Editor

Simon Petrie

## Design and Production

Kasra Yousefi

## Editorial Advisory Board

David Durrheim,  
Mark Ferson, John Kaldor,  
Martyn Kirk and Linda Selvey

## Website

<http://www.health.gov.au/cdi>

## Contacts

Communicable Diseases Intelligence is produced by:  
Health Protection Policy Branch  
Office of Health Protection  
Australian Government  
Department of Health  
GPO Box 9848, (MDP 6)  
CANBERRA ACT 2601

## Email:

[cdi.editor@health.gov.au](mailto:cdi.editor@health.gov.au)

## Submit an Article

You are invited to submit your next communicable disease related article to the Communicable Diseases Intelligence (CDI) for consideration. More information regarding CDI can be found at:  
<http://health.gov.au/cdi>.

Further enquiries should be directed to:

[cdi.editor@health.gov.au](mailto:cdi.editor@health.gov.au)

# Australian Gonococcal Surveillance Programme, 1 January to 31 March 2018

Monica M Lahra and Rodney P Enriquez

The World Health Organisation Collaborating Centre for STI and AMR and Neisseria Reference Laboratory, New South Wales Health Pathology, Prince of Wales Hospital, Randwick, NSW, 2031 for The National Neisseria Network, Australia

## Introduction

The National Neisseria Network (NNN), Australia, comprises reference laboratories in each state and territory that report data on sensitivity to an agreed group of antimicrobial agents for the Australian Gonococcal Surveillance Programme (AGSP). The antibiotics tested are penicillin, ceftriaxone, azithromycin and ciprofloxacin. These are current or potential agents used for the treatment of gonorrhoea. Azithromycin combined with ceftriaxone is the recommended treatment regimen for gonorrhoea in the majority of Australia. However, there are substantial geographic differences in susceptibility patterns in Australia and in certain remote regions of the Northern Territory and Western Australia gonococcal antimicrobial resistance rates are low, and an oral treatment regimen comprising amoxicillin, probenecid and azithromycin is recommended for the treatment of gonorrhoea. Additional data on other antibiotics are reported in the AGSP Annual Report. The AGSP has a programme-specific quality assurance process.

## Results

A summary of the proportion of isolates with decreased susceptibility (DS) to ceftriaxone, and the proportion resistant to azithromycin, penicillin, and ciprofloxacin for Quarter 1 2018 is shown in Table 1.

### Ceftriaxone

In the first quarter of 2018 the proportion of isolates with ceftriaxone DS in Australia was 1.7%, slightly higher than the proportion in the first quarter of 2017, and the annual proportion for 2017. Of note there were two isolates reported in Australia that had high minimal inhibitory concentration (MIC) values to ceftriaxone (0.25mg/L and 0.50mg/L), that also had high level resistance to azithromycin MIC (>256mg/L), and were resistant to penicillin and ciprofloxacin, but susceptible to spectinomycin and gentamicin. Genetic analyses showed these two strains were indistinguishable.<sup>1</sup> Both

strains were isolated from persons residing in Queensland. This was the first time *Neisseria gonorrhoeae* (NG) strains with an extensively drug resistant profile have been reported in Australia; a strain with a similar profile has also been reported in the United Kingdom.<sup>2</sup>

The category of ceftriaxone DS as reported by the AGSP includes the MIC values 0.06 and  $\geq 0.125$  mg/L, and the national trend since 2010 is shown in Table 2.

A summary of ceftriaxone DS strains that were resistant to penicillin and ciprofloxacin, or isolated from extragenital sites (rectal and pharyngeal) for Quarter 1, 2018 by state or territory, and by sex (male/female), are shown in Table 3.

**Table 1: Gonococcal isolates showing decreased susceptibility to ceftriaxone and resistance to azithromycin, penicillin, and ciprofloxacin, Australia, 1 January to 31 March 2018, by state or territory**

State or Territory	Number of isolates tested	Decreased Susceptibility		Resistance					
		Ceftriaxone MIC $\geq 0.06$ mg/L		Azithromycin MIC $\geq 1.0$ mg/L		Penicillin <sup>a</sup> MIC $\geq 1.0$ mg/L		Ciprofloxacin MIC $\geq 1.0$ mg/L	
		n	%	n	%	n	%	n	%
Australian Capital Territory	58	0	0	4	6.9	6	10.3	7	12.1
New South Wales	823	4	0.5	45	5.5	206	25.0	243	29.5
Queensland	300	6	2.0	32	10.7	81	27.0	91	30.3
South Australia	68	0	0	3	4.4	31	45.6	36	52.9
Tasmania	11	1	9.1	0	0	3	27.3	2	18.2
Victoria	688	23	3.3	44	6.4	145	21.1	171	24.9
Northern Territory Urban & Rural	24	0	0	1	4.2	4	16.7	0	0
Northern Territory Remote	32	0	0	0	0	1	3.1	2	6.3
Western Australia Urban & Rural	177	4	2.3	3	1.7	41	23.2	45	25.4
Western Australia Remote	24	0	0	0	0	1	4.2	1	4.2
<b>AUSTRALIA</b>	<b>2,205</b>	<b>38</b>	<b>1.7</b>	<b>132</b>	<b>6.0</b>	<b>519</b>	<b>23.5</b>	<b>598</b>	<b>27.0</b>

a Penicillin resistance includes MIC value of  $\geq 1.0$  mg/L, or penicillinase production.

Table 2: Percentage of gonococcal isolates with decreased susceptibility to ceftriaxone (MIC 0.06 and  $\geq 0.125$  mg/L), Australia, 2010 to 2017, and 1 January to 31 March 2018.

Ceftriaxone MIC mg/L	2010	2011	2012	2013	2014	2015	2016	2017	2018 Q1
0.06	4.80%	3.20%	4.10%	8.20%	4.80%	1.70%	1.65%	1.02%	1.60%
$\geq 0.125$	0.10%	0.10%	0.30%	0.60%	0.60%	0.10%	0.05%	0.04%	0.10%

Table 3: Percentage of gonococcal isolates with decreased susceptibility to ceftriaxone (MIC  $\geq 0.06$  mg/L) and that were penicillin (Pen) and ciprofloxacin (Cip) resistant (R), isolated from extragenital sites, and by sex, Australia, 1 January to 31 March 2018.

State or Territory	Total		Pen R + Cip R		Males		Females		Extragenital sites	
	n	%	n	%	n	%	n	%	n	%
Australian Capital Territory	0	0	0	0	0	0	0	0	0	0
New South Wales	4	75	3	75	1	25	3	75	2	50
Queensland	6	50	3	50	4	67	2	33	2	33
South Australia	0	0	0	0	0	0	0	0	0	0
Tasmania	1	100	1	100	1	100	0	0	0	0
Victoria	23	61	14	61	17	74	6	26	8	35
Northern Territory Urban & Rural	0	0	0	0	0	0	0	0	0	0
Northern Territory Remote	0	0	0	0	0	0	0	0	0	0
Western Australia Urban & Rural	4	100	4	100	2	50	2	50	1	25
Western Australia Remote	0	0	0	0	0	0	0	0	0	0
<b>AUSTRALIA</b>	<b>38</b>	<b>65.8</b>	<b>25</b>	<b>65.8</b>	<b>25</b>	<b>65.8</b>	<b>13</b>	<b>34.2</b>	<b>13</b>	<b>34.2</b>

**Table 4: Percentage of gonococcal isolates with resistance to azithromycin MIC  $\geq$ 1.0 mg/L, Australia, 2012 to 2017, and 1 January to 31 March 2018**

Azithromycin Resistance	2012	2013	2014	2015	2016	2017	2018 Q1
MIC $\geq$ 1mg/L	1.3%	2.1%	2.5%	2.6%	5.0%	9.3%	6.0%

## Azithromycin

In the first quarter of 2018, the proportion of isolates with resistance to azithromycin in Australia was 6.0%, lower than the proportion reported nationally for 2017 (9.3%), but three times the level reported in Australia for 2013–2015 (2.1%–2.6%).<sup>3</sup> Initially, in 2016 the highest incidence of azithromycin resistance was reported from South Australia (19.5% in 2016, compared with 2.8% in 2015), where an outbreak of strains with low level azithromycin was reported in 2016 with a subsequent change in treatment guidelines.<sup>4</sup> Globally there have been increasing reports of azithromycin resistance in *N. gonorrhoeae*.<sup>5</sup>

In Quarter 1 2018, most states reported isolates with resistance to azithromycin, with the exception of Tasmania, remote Northern Territory and remote Western Australia. The states that reported an increase in the proportion of NG isolates with resistance to azithromycin when compared with the annual data for 2017 were Queensland, the Australian Capital Territory and urban Northern Territory, while the other states reported a decrease from the 2017 annual data.

The national trend of azithromycin resistance in isolates since 2012 is shown in Table 4.

Dual therapy of ceftriaxone plus azithromycin is the recommended treatment for gonorrhoea as a strategy to temper development of more widespread resistance. Patients with infections in extragenital sites, where the isolate has decreased susceptibility to ceftriaxone, are recommended to have test of cure cultures collected. Continued surveillance to monitor *N. gonorrhoeae* with elevated MIC values, coupled with sentinel site surveillance in high risk populations, remains

important to inform therapeutic strategies, to identify incursion of resistant strains, and to detect instances of treatment failure.

## References

1. Whiley DM, Jennison A, Pearson J, Lahra MM. Genetic characterisation of *Neisseria gonorrhoeae* resistant to both ceftriaxone and azithromycin. *Lancet Infect Dis*. 2018;18(7):717–8.
2. European Centre for Disease Prevention and Control. Rapid Risk Assessment: Extensively drug-resistant (XDR) *Neisseria gonorrhoeae* in the United Kingdom and Australia. 2018. Available online: <https://ecdc.europa.eu/en/publications-data/rapid-risk-assessment-extensively-drug-resistant-xdr-neisseria-gonorrhoeae-united>
3. Lahra MM, Enriquez RP. Australian Gonococcal Surveillance Programme Annual Report, 2016. *Commun Dis Intell* (2018). 2018;42. pii: S2209-6051(18)00013-1.
4. Lahra MM, Ward A, Trembizki E, Hermanson J, Clements E, Lawrence A, et al. Treatment guidelines after an outbreak of azithromycin-resistant *Neisseria gonorrhoeae* in South Australia. *Lancet Infect Dis*. 2017;17(2):133–4.
5. Unemo M. Current and future antimicrobial treatment of gonorrhoea—the rapidly evolving *Neisseria gonorrhoeae* continues to challenge. *BMC Infect Dis*. 2015;15:364.